Matthew P. Giannetti, MD
Instructor, Harvard Medical School
Allergy and Immunology
Associate Director
Brigham and Women’s Hospital Mastocytosis Center
Boston, Massachusetts
Anne L. Maitland, MD, PhD
Director, Allergy & Immunology
Metrodora Institute
Assistant Professor
Department of Medicine, Division of Allergy & Clinical Immunology
Icahn School of Medicine
New York, New York
Matthew J. Hamilton, MD
Assistant Professor of Medicine
Harvard Medical School
Lead Gastroenterologist
Brigham and Women’s Hospital Mastocytosis Center
Boston, Massachusetts
Lauren M. Madigan, MD
Assistant Professor of Dermatology
University of Utah
Practicing Clinician
University Medical Center and Huntsman Cancer Institute
Salt Lake City, Utah

Target Audience

The design of this activity addresses the needs of clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced systemic mastocytosis (SM).

Program Overview

Nonadvanced SM is a challenging disorder to diagnose and manage due to the heterogeneity of symptoms, anaphylactic triggers, and complicated therapeutic paradigm. In this unique and engaging Call-a-Colleague program, a panel of multidisciplinary faculty will discuss evolving diagnostic and management strategies for nonadvanced SM.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe key pathophysiologic processes in SM, with a focus on potential clinical manifestations and the rationale for new targeted therapies
  • Evaluate patients with suspected nonadvanced SM to characterize symptoms, disease burden, and results from appropriate ancillary testing
  • Discuss clinical trial evidence and appropriate use of targeted treatment options for nonadvanced SM
  • Individualize treatment regimens for nonadvanced SM to reflect clinical evidence for efficacy and safety, patient-reported outcomes, and shared clinical decision-making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Relevant Financial Relationships

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Matthew P. Giannetti, MD: Consulting Fees: Blueprint Medicines, Cogent Biosciences; Contracted Research: Blueprint Medicines; Medical Safety Board: Inmagene

Anne L. Maitland, MD, PhD: Consulting Fees: Blueprint Medicines, Cogent Biosciences, Inc., TerSera Therapeutics, LLC; Speakers' Bureau: Blueprint Medicines

Matthew J. Hamilton, MD: Consulting Fees: Blueprint Medicines, InveniAI, LLC

Lauren M. Madigan, MD: Consulting Fees: Blueprint Medicines

The planners and managers have reported no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For information about this program, please contact us at info@exchangecme.com.

Begin Activity
available resources
meeting slides
interactive presentation
linked resources
Suggested Reading

Answering the Call in Nonadvanced Systemic Mastocytosis

Targeted Approaches to Patient Management